Furosemide and isosorbide dinitrate
ApprovedSmall molecule
Furosemide and isosorbide dinitrate is one of 12 small molecule programs targeting Pulmonary Edema. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Pulmonary Edema
#DrugCompanyPhaseTrials
1Isordil
AstraZenecaApproved
Diamox
TevaApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Nitrostat
VViatris Specialty LLC
Phase 2
Alka-Seltzer
AAbbott
Phase 2
Furosemide and isosorbide dinitrate
JJohannes Grand
Approved
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Viagra
VViatris Specialty LLC
Phase 1
Procardia
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- JJohannes Grand